Analyst picks & changes

Amgen Inc.

Jeffrey Casdin of Oppenheimer & Co. changed his rating on Amgen Inc. to "market performer" from "buy," following publication of the company's fourth quarter earnings. He said the renewed near-term growth of

Epogen

erythropoietin isn't enough to overcome

Read the full 408 word article

How to gain access

Continue reading with a
two-week free trial.